IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
IQVIA HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$265.88−1.02 (-0.38%)
Close on Oct 19, 2026
- Market cap
- $44.48B
- P/E (TTM)
- 33.0
- Dividend yield
- –
IQVIA HOLDINGS INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Solutions | $8.90B | $8.53B | $8.40B | $7.92B | $7.56B | $5.76B | $5.79B | $5.47B | $5.11B | $4.74B | 54.5% | +4.3% |
| Technology And Analytics Solutions | $6.63B | $6.16B | $5.86B | $5.75B | $5.53B | $4.86B | $4.49B | $4.14B | $3.68B | $1.15B | 40.6% | +7.6% |
| Contract Sales & Medical Solutions | $788.00M | $718.00M | $727.00M | $743.00M | $784.00M | $741.00M | $814.00M | $810.00M | $915.00M | $930.00M | 4.8% | +9.7% |
| Integrated Engagement Services [Member] | – | – | – | – | – | – | – | – | $783.00M | $797.00M | – | – |
| Commercial Solutions | – | – | – | – | – | – | – | – | $3.63B | $1.09B | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $7.75B | $7.36B | $7.55B | $7.05B | $6.85B | $5.42B | $5.46B | $5.00B | $4.61B | $3.25B | 47.5% | +5.3% |
| Europe and Africa | $5.19B | $4.92B | $4.46B | $4.37B | $4.36B | $3.70B | $3.48B | $3.45B | $3.29B | $2.22B | 31.8% | +5.4% |
| Asia-Pacific | $3.38B | $3.13B | $2.97B | $3.00B | $2.67B | $2.25B | $2.15B | $1.97B | $1.81B | $1.34B | 20.7% | +8.0% |
From the segment and revenue-disaggregation notes of Iqvia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.